Family of Penn Hills officer who died by suicide after Lasik surgery receives letter from FDA
Ryan Kingerski's family members said the 26-year-old's Lasik eye surgery led to unbearable pain. They say if doctors and industry leaders highlighted or even conveyed the real, much higher complication numbers, patients would be better educated about the risks. They believe the industry is trying to downplay complications and silence people like their late son.
FDA sends letter to Ryan Kingerski's family
In an interview with KDKA-TV earlier this year, mom Stefanie Kingerski described her son Ryan as "witty, charming, smart."
But the dedicated Penn Hills police officer died by suicide after struggling with debilitating side effects following Lasik, which is an elective eye surgery.
"He kept saying about how bad the pain in his head was. He had a terrible headache and wasn't able to focus, and the vision and the blurriness and everything else," dad Tim Kingerski previously explained.
Now Tim and Stefanie Kingerski are fighting for industry accountability, sharing with KDKA Investigates a new response letter they say they received from the Food and Drug Administration, signed by the FDA's consumer team. They say it proves acknowledgement of what they call a gross underreporting of adverse side effects.
It says the FDA inspector "has been following these Laser Lasik incidences for several years. He explained there is under-reporting by the Ophthalmic Clinics because they are not submitting the required patient injuries to the FDA."
The letter also says the FDA is "actively looking into sending out a 'warning notice' to the public about the risks" of Lasik.
FDA adviser who approved Lasik says he regrets it
"I tell people that ask me, and even if they don't ask, it's 'trust but verify.' If they say it's 1%, go look it up, go find out what is the actual rate," said retired FDA adviser Dr. Morris Waxler.
Waxler voted to approve Lasik three decades ago, but now he says he regrets it and is one of Lasik's biggest critics after his independent review of the data.
"They'll make a long list if they provide any information about informed consent. Provide a long list of things that could happen, but they will not provide actual percentages because they know the percentages are really high. They're 10% to 20% to 30%, some as high as 75%, depending on what you're measuring."
The FDA warns on its website that some patients may lose vision and develop debilitating visual symptoms, adding that the long-term safety and effectiveness of Lasik surgery is not known.
Still, supporters of Lasik tout a 1% complication rate.
"And all I can do is provide the information, and they can look it up. And you can ask the surgeon, 'Well, why don't you cite that study? Why are you ignoring that study? Why are you not pointing this out? Is there something wrong with those studies? Why have you ignored this whole body of literature?' So you need to ask them questions," Waxler said.
Red flags for any elective procedure include you feel like you're receiving a sales pitch, a surgeon promises perfection, there's pressure to make a decision quickly, side effects are not highlighted or minimized and it feels more like a business transaction than medical care.
Waxler points out Lasik is very attractive to young people, public servants, like police officers like Ryan, and military members.
U.S. congressman talking with FDA
The Kingerski family said Congressman Chris Deluzio is now looking into this, given his military background, and hoping to find answers, as well.
"Congressman Deluzio's office is engaging with the FDA to see what can be done to avoid terrible tragedies like Officer Kingerski's from happening in the future. Our brave cops have hard enough jobs; nobody should worry about losing their life after something like this," his spokesperson said in a statement.
KDKA-TV also reached out directly to the FDA and was told, "The FDA does not discuss possible or ongoing investigations."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
9 minutes ago
- WebMD
RSV Vaccine Age 50+: What a New CDC Update Means for You
July 3, 2025 – The CDC published a new recommendation this week calling for some adults ages 50 to 59 to get vaccinated for respiratory syncytial virus (RSV). Public health experts predict that if 20% of all newly eligible U.S. adults get vaccinated, it would prevent about 5,200 hospitalizations, 1,100 ICU stays, and 333 deaths annually. Here's what you should know, and what the new recommendation means for you. What is the RSV vaccine? Three versions are approved by the FDA: Pfizer's Abrysvo, GSK's Arexvy, and Moderna's mRESVIA. Any of these can protect you against respiratory syncytial virus, which infects the lungs and respiratory tract. Most RSV cases are mild, but they can be serious in children, older adults, and people with compromised immune systems. Who is the new recommendation for? Adults ages 50 to 59 with certain medical conditions, or who live in a nursing home or rural community with limited medical care access. Who was the vaccine already recommended for? Adults ages 60 to 74 with risk factors, and all people ages 75 and older. The vaccine is also recommended for people who are between 32 and 36 weeks of pregnancy during RSV season (from September through January), to protect newborns during their first RSV season. Why did the recommended age change? Federal health officials updated the recommendation because new evidence supports RSV vaccination for adults in the 50-59 age group who have health conditions. This change comes after a previous call for more research – particularly on potential risks like Guillain-Barré syndrome (a neurological condition). The latest data shows that vaccination reduces a person's risk of hospitalization due to RSV by 75%, leading health officials to conclude that the benefits outweigh the risks for the newly recommended age group. I already got an RSV vaccine. Should I get another one this year? No, RSV is a not an annual vaccine. When should I get the RSV shot? The best time for adults to get an RSV vaccine is late summer or early fall, the CDC says, but it's OK to get it at any time, such as during your routine physical appointment. The optimal months are August through October, before the rise of respiratory viruses during late fall and winter. I ' m over 50 and haven ' t gotten an RSV vaccine before. How do I know if I should get one? If you're 75 or older, the CDC recommends you get vaccinated against RSV. If you're between 50 and 74, you may be eligible if you're at high risk of severe RSV illness. Talk to your doctor, or if you know you have certain risk factors, you can ask for the vaccine. These risk factors include: Chronic cardiovascular disease (heart failure, coronary artery disease, congenital heart disease) Chronic lung or respiratory disease, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, interstitial lung disease, and cystic fibrosis End-stage renal disease or dependence on hemodialysis or other renal replacement therapy Type 1 or type 2 diabetes complicated by chronic kidney disease, neuropathy, retinopathy, or other end-organ damage Type 1 or type 2 diabetes requiring treatment with insulin or a sodium-glucose cotransporter 2 (SGLT2) inhibitor Neurologic or neuromuscular conditions that impair breathing (post-stroke dysphagia, amyotrophic lateral sclerosis, muscular dystrophy) Chronic liver disease, such as cirrhosis Chronic hematologic conditions, such as sickle cell disease or thalassemia Severe obesity (body mass index of 40 or higher) A compromised immune system Residence in a nursing home Other chronic medical conditions or risk factors a doctor believes could increase the risk of severe disease due to viral respiratory infection (such as frailty, a potentially undiagnosed medical condition, or living in a rural community with limited medical care access)
Yahoo
21 minutes ago
- Yahoo
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Year to date, REGN's shares have lost 22.9% compared with the industry's 0.6% decline. Image Source: Zacks Investment Research The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population. With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM. The approval strengthens REGN's oncology portfolio. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024. The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025. The successful development of these oncology drugs should be a great boost for REGN. The decline in lead drug Eylea sales is a concern for REGN. Eylea sales are under pressure due to competition from Roche's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea. REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Associated Press
an hour ago
- Associated Press
Medicaid, food aid recipients worry about safety net cuts in bill sent to Trump
JEFFERSON CITY, Mo. (AP) — Supporters of the sweeping tax and spending legislation that Congress has sent to President Donald Trump say the changes to Medicaid, food aid and other programs will encourage personal responsibility and halt those scamming the system. Critics of the bill, given final congressional approval Thursday, say the requirements will upend lives. Here's a look at what people are saying about the bill. Work requirements added for accessing more federal benefits To enroll and stay on Medicaid, many ages 19 through 64 would be required to work, go to school or perform at least 80 hours of community service a month. The Medicaid work requirement would apply to people in 40 states who are enrolled through expanded access that states agreed to put in place since 2014. Ten states, including Texas and Florida, did not expand the program. For the Supplemental Nutrition Assistance Program, or SNAP, which already requires adults ages 18 to 55 to work, working would become mandatory for many until they turn 65. For both benefits, there would be exceptions, including for parents who are caregivers to children under age 14. Most people covered by Medicaid already meet the work requirement or qualify for an exception. The requirements are sparking worry for some enrollees Theresa Gibbs, who lost her job as a school bus driver, is enrolled in both Medicaid and SNAP. She likely would be exempt from the work mandate because she has three children under age 14. But Gibbs said she is applying for jobs anyway. 'I don't think people should just live off the state if they're perfectly capable to work,' said Gibbs, 34, of Jefferson City, Missouri. But the changes worry others. Amanda Hinton, 39, of St. Martins, Missouri, receives Medicaid and SNAP benefits. She puts in enough hours at a part-time gas station job to likely meet the new requirements but is concerned should her fibromyalgia, which causes pain and fatigue, keep her from working for a time. 'I'm panicked. I mean I have some chronic health conditions that are not curable, and I rely on my medication to help me just get through the day,' she said. 'And without my Medicaid, I couldn't afford these.' Brittany Phillips, 32, of Greensboro, North Carolina, said being on Medicaid has helped her stay afloat both financially and health-wise while she works a temporary, remote medical services job paying about $600 weekly. 'I do believe that Medicaid should be available for everyone regardless of who they are -- regardless of capacity, faculty -- everyone should have Medicaid,' she said. It's not just the work requirement; it's also the paperwork The nonpartisan Congressional Budget Office estimates that 11.8 million fewer people could have health insurance by 2034 because of the changes, which also include booting off non-citizens who are not in the U.S. permanently and legally. And that doesn't include those who could lose coverage for other reasons. Advocates say that even people who are covered by exceptions to the work requirement could lose their Medicaid coverage. One major reason is a requirement that people's eligibility would be assessed at least every six months. 'Every additional paper someone has to submit separately from their application,' said Deborah Steinberg, a senior health policy analyst at the Legal Action Center, 'you lose people.' Julia Bennker, who runs an in-home daycare in Eau Claire, Wisconsin, relies on SNAP and Medicaid and has had paperwork issues under existing Medicaid requirements. She said that earlier this year, she didn't have health coverage for a month after she was told her forms were late — though she believes she submitted them on time. That meant going a month without therapy and needing to reschedule another appointment with a prescriber. Some of the conditions that would trigger exceptions — mental illness or substance use disorder — are not currently tallied in Medicaid computer systems. 'It's not like you wave a magic wand and everyone who should be exempt is exempt,' said Hannah Wesolowski, chief advocacy officer for the National Alliance on Mental Illness. States will face pressure - and deadlines - to revamp their programs State health care and social services agencies will have to rework their computer systems to account for the various changes while also dealing with federal funding reductions. That's cause for concern for some health care advocates. The legislation requires all states to shoulder more of the administrative costs of SNAP starting in 2027 and, for the first time, could force some states to pay for a portion of food assistance benefits starting in 2028. States also must implement the Medicaid work requirement by 2027. 'It will be a very tight and difficult timeline for many of these states,' said Sophia Tripoli, senior health policy director at Families USA, a health care advocacy organization. 'There's a huge cost burden on states from the administrative side just to stand up these systems.' Julieanne Taylor, a lawyer at the Charlotte Center for Legal Advocacy in North Carolina, said her organization's clients already face delays in verifications for the food program. 'To add more to them, it's going to be a disaster,' she said. 'It's going to cause people to drop off because they're like, 'I don't want to have to do this every year or every six months.'' Rural hospitals could face financial struggles The bill could also put rural hospitals at financial risk, experts say, because it seeks to cap the taxes that states impose on hospitals and other health care providers in a way that boosts Medicaid funding. The nonprofit KFF, which studies health care issues, estimates that Medicaid spending in rural areas would decrease by $155 billion over the next decade under the bill. 'While there are already a number of small and rural hospitals that are vulnerable,' said R. Kyle Kramer, CEO of Day Kimball Hospital in Putnam, Connecticut, 'it's going to lead to a lot of closures.' The bill includes a $50 billion fund to partially offset those reductions. Planned Parenthood would lose federal money Federal taxpayer money is already barred from paying for abortions in most cases. The bill would also ban federal funds going to Planned Parenthood, the nation's largest abortion provider, for other purposes like family planning programs and cancer screenings. The group says that one-third of its roughly 600 clinics across the U.S. could face closure as a result of the legislation, and that states where abortion is legal would be hardest hit. At least one other group says it also stands to lose funding because of the provision. Maine Family Planning has 19 sites and subcontracts with other health care organizations, including Planned Parenthood, to provide services at other locations across the rural state. ___ Mulvihill reported from Cherry Hill, New Jersey. Susan Haigh in Hartford, Connecticut, and Gary D. Robertson in Raleigh, North Carolina, contributed to this report.
